Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2012

Open Access 01-12-2012 | Research article

Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease

Authors: Mostafa Abdel-Aziz El-Hodhod, Ahmad Mohamed Hamdy, Amal Ahmed Abbas, Sherine George Moftah, Alhag Ahmed Mohamed Ramadan

Published in: BMC Gastroenterology | Issue 1/2012

Login to get access

Abstract

Background

Diminished bone mineral density (BMD) is of significant concern in pediatric inflammatory bowel disease (IBD). Exact etiology is debatable. The recognition of fibroblast growth factor 23 (FGF23), a phosphaturic hormone related to tumor necrosis factor alpha (TNF-α) makes it plausible to hypothesize its possible relation to this pathology.

Methods

In this follow up case control study, BMD as well as serum levels of FGF23, calcium, phosphorus, alkaline phosphatase, creatinine, parathyroid hormone, 25 hydroxy vitamin D3 and 1, 25 dihydroxy vitamin D3 were measured in 47 children with IBD during flare and reassessed in the next remission.

Results

Low BMD was frequent during IBD flare (87.2%) with significant improvement after remission (44.7%). During disease flare, only 21.3% of patients had vitamin D deficiency, which was severe in 12.8%. During remission, all patients had normal vitamin D except for two patients with Crohn’s disease (CD) who remained vitamin D deficient. Mean value of serum FGF23 was significantly higher among patients with IBD during flare compared to controls. It showed significant improvement during remission but not to the control values. 1, 25 dihydroxy vitamin D3, FGF23, serum calcium and urinary phosphorus were significant determinants of BMD in IBD patients.

Conclusions

We can conclude that diminished BMD in childhood IBD is a common multifactorial problem. Elevated FGF23 would be a novel addition to the list of factors affecting bone mineral density in this context. Further molecular studies are warranted to display the exact interplay of these factors.
Literature
1.
Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K: Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13 (1): 42-50. 10.1002/ibd.20006.CrossRefPubMed
2.
Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR: Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997, 76 (4): 325-329. 10.1136/adc.76.4.325.CrossRefPubMedPubMedCentral
3.
Ezzat Y, Hamdy K: The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010, 13 (3): 259-265. 10.1111/j.1756-185X.2010.01542.x.CrossRefPubMed
4.
Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R: Cucchiara S Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13 (4): 416-423. 10.1002/ibd.20039.CrossRefPubMed
5.
Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G: Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol. 2005, 3 (2): 122-132. 10.1016/S1542-3565(04)00663-9.CrossRefPubMed
6.
Hessov I, Mosekilde L, Melsen F, Fasth S, Hultén L, Lund B, Lund B, Sørensen OH: Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol. 1984, 19 (5): 691-696.PubMed
7.
Bernstein CN, Bector S, Leslie WD: Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol. 2003, 98 (11): 2468-2473. 10.1111/j.1572-0241.2003.07676.x.CrossRefPubMed
8.
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K: Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004, 53 (8): 1129-1136. 10.1136/gut.2003.036657.CrossRefPubMedPubMedCentral
9.
Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 1996, 10 (5): 777-786. 10.1046/j.1365-2036.1996.63205000.x.CrossRefPubMed
10.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001, 98 (11): 6500-6505. 10.1073/pnas.101545198.CrossRefPubMedPubMedCentral
11.
Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T: Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab. 2004, 89 (8): 3979-3982. 10.1210/jc.2004-0406.CrossRefPubMed
12.
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and Xlinked hypophosphatemia. N Engl J Med. 2003, 348: 1656-1663. 10.1056/NEJMoa020881.CrossRefPubMed
13.
Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002, 143 (8): 3179-3182. 10.1210/en.143.8.3179.CrossRefPubMed
14.
Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ: FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006, 104 (1): p23-p32. 10.1159/000093277.CrossRefPubMedPubMedCentral
15.
Bowe AE, Finnegan R, de Beur SM Jan, Cho J, Levine MA, Kumar R, Schiavi SC: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001, 284: 977-981. 10.1006/bbrc.2001.5084.CrossRefPubMed
16.
Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, et al: Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int. 2007, 81 (6): 415-420. 10.1007/s00223-007-9067-4. Epub 2007 Nov 29CrossRefPubMed
17.
Noguchi M, Hiwatashi N, Liu Z, Toyota T: Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 1998, 43: 203-209. 10.1136/gut.43.2.203.CrossRefPubMedPubMedCentral
18.
Uno JK, Kolek OI, Hines ER, Xu H, Timmermann BN, Kiela PR, Ghishan FK: The role of tumor necrosis factor alpha in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology. 2006, 131 (2): 497-509. 10.1053/j.gastro.2006.05.020.CrossRefPubMed
19.
Working IBD: Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis–the Porto criteria. J Pediatr Gastroenterol Nutr. 2005, 41 (1): 1-7. 10.1097/01.MPG.0000163736.30261.82.CrossRef
20.
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AMl: Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007, 133 (2): 423-432. 10.1053/j.gastro.2007.05.029. Epub 2007 May 21CrossRefPubMed
21.
Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN: Is an abbreviated Pediatric Crohn’s disease activity index better than the original?. J Pediatr Gastroenterol Nutr. 2004, 39: 68-72. 10.1097/00005176-200407000-00014.CrossRefPubMed
22.
WHO: a: Child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. 2006, WHO, Geneva
23.
Wadsworth C, Wadsworth E: Efficacy of latex agglutination and quantification methods for determination of C-reactive protein (CRP) in pediatric sera. Clin Chim Acta. 1984, 138 (3): 309-318. 10.1016/0009-8981(84)90138-4.CrossRefPubMed
24.
25.
Chapoteau E, Czech BP, Zazulak W, Kumar A: New reagent for colorimetric assay of calcium in serum. Clin Chem. 1993, 39 (9): 1820-1824.PubMed
26.
Rubino L, Catapano V, Guerra G: Determination of inorganic phosphorus in serum: Evaluation of three methods applied to the Technicon RA-1000 analyzer. J Automat Chem. 1989, 11 (4): 164-167. 10.1155/S1463924689000350.CrossRefPubMedPubMedCentral
27.
Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL: Determination of vitamin D status by radioimmunoassay with an125I-labeled tracer. Clin Chem. 1993, 39: 529-533.PubMed
28.
Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS: Vitamin D status in children, adolescents, and young adults with Crohn’s disease. Am J Clin Nutr. 2002, 76: 1077-1081.PubMed
29.
Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ: Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004, 158: 531-537. 10.1001/archpedi.158.6.531.CrossRefPubMed
30.
Clive DR, Sudhaker D, Giacherio D, Gupta M, Schreiber MJ, Sackrison JL, MacFarlane GD: Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin Biochem. 2002, 35 (7): 517-521. 10.1016/S0009-9120(02)00378-8.CrossRefPubMed
31.
Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D: Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006, 91 (6): 2055-2061. 10.1210/jc.2005-2105. Epub 2006 Mar 21CrossRefPubMed
32.
van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM: Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child. 2002, 87: 341-347. 10.1136/adc.87.4.341.CrossRefPubMedPubMedCentral
33.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of Hand and Wrist. 1959, Stanford University Press, Stanford
34.
Barnes C, Wong P, Egan B, Cameron F, Jones G, Ekert H, Monagle P: Reduced bone density among children with severe hemophilia. Pediatrics. 2004, 114: 177-181. 10.1542/peds.114.1.177.CrossRef
35.
Buller H, Chin S, Kirschner B, Kohn J, Markowitz J, Moore D, Murch S, Taminiau J: Inflammatory Bowel Disease in Children and Adolescents: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2002, 35: S151-S158.CrossRefPubMed
36.
D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology. 1999, 116: 1029-1034. 10.1016/S0016-5085(99)70005-3.CrossRefPubMed
37.
Alexander F, Sarigol S, DiFiore J: Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. J Pediatr Surg. 2003, 38 (1): 78-82. 10.1053/jpsu.2003.50015.CrossRefPubMed
38.
Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA: Bone mineral density in children and young adults with Crohn’s disease. Inflamm Bowel Dis. 1999, 5: 161-166.CrossRefPubMed
39.
Levine A, Mishna L, Ballin A, Givoni S, Dinari G, Hartman C: Use of Quantitative Ultrasound to Assess Osteopenia in Children With Crohn’s Disease. J Pediatr Gastroenterol Nutr. 2002, 35: 169-172. 10.1097/00005176-200208000-00012.CrossRefPubMed
40.
Schmidt S, Mellström D, Norjavaara E, Sundh SV, Saalman R: Low bone mineral density in children and adolescents with inflammatory bowel disease: A population-based study from Western Sweden. Inflamm Bowel Dis. 2009, 15 (12): 1844-1850. 10.1002/ibd.20962.CrossRefPubMed
41.
Herzog D, Bishop N, Glorieux F, Seidman EG: Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis. 1998, 4: 261-267. 10.1002/ibd.3780040402.PubMed
42.
Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P: Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J Pediatr Gastroenterol Nutr. 2004, 38: 276-281. 10.1097/00005176-200403000-00008.CrossRefPubMed
43.
Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, et al: Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Bone. 2007, 40 (4): 1073-1077. 10.1016/j.bone.2006.11.015. Epub 2007 Jan 19CrossRefPubMed
44.
Bhambri R, Naik V, Malhotra N, Taneja S, Rastogi S, Ravishanker U, et al: Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom. 2006, 9 (1): 120-127. 10.1016/j.jocd.2005.11.001. Epub 2006 Mar 27CrossRefPubMed
45.
Zerwekh JE: Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008, 87 (4): 1087S-1091S.PubMed
46.
Fukumoto S: Post-translational modification of Fibroblast Growth Factor 23. Ther Apher Dial. 2005, 9 (4): 319-322. 10.1111/j.1744-9987.2005.00289.x.CrossRefPubMed
47.
Yamamoto R, Minamizaki T, Yoshiko Y, Yoshioka H, Tanne K, Aubin JE, et al: 1 alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro. J Endocrinol. 2010, 206 (3): 279-286. 10.1677/JOE-10-0058. Epub 2010 Jun 8CrossRefPubMedPubMedCentral
48.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004, 19: 429-435.CrossRefPubMed
49.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007, 117: 4003-4008.PubMedPubMedCentral
50.
Walther F, Fusch C, Radke M, Beckert S, Findeisen A: Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr. 2006, 43 (1): 42-51. 10.1097/01.mpg.0000228105.91240.80.CrossRefPubMed
51.
Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al: Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2004, 20 (6): 607-614. 10.1111/j.1365-2036.2004.02152.x.CrossRefPubMed
52.
Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, et al: Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment Pharmacol Ther. 2004, 20 (8): 851-857. 10.1111/j.1365-2036.2004.02097.x.CrossRefPubMed
53.
Ghishan FK, Kiela PR: Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2011, 300: G191-G201. 10.1152/ajpgi.00496.2010.CrossRefPubMed
54.
Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 1994, 9: 1137-1141.CrossRefPubMed
55.
Sylvester FA: IBD and skeletal health: children are not small adults!. Inflamm Bowel Dis. 2005, 11: 1020-1023.CrossRefPubMed
Metadata
Title
Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease
Authors
Mostafa Abdel-Aziz El-Hodhod
Ahmad Mohamed Hamdy
Amal Ahmed Abbas
Sherine George Moftah
Alhag Ahmed Mohamed Ramadan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2012
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-12-44

Other articles of this Issue 1/2012

BMC Gastroenterology 1/2012 Go to the issue

Research article

Diagnosing celiac disease by video capsule endoscopy (VCE) when esophogastroduodenoscopy (EGD) and biopsy is unable to provide a diagnosis: a case series

Research article

Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial

Research article

The balance between two isoforms of LEF-1 regulates colon carcinoma growth

Research article

Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units

Research article

Association of polymorphism of PTPN 11 encoding SHP-2 with gastric atrophy but not gastric cancer in Helicobacter pylori seropositive Chinese population

Research article

A gluten-free diet effectively reduces symptoms and health care consumption in a Swedish celiac disease population

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits